{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:24:05Z","timestamp":1790421845513,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Cleveland BioLabs, Inc. NCI Cancer Center Support Grant"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acute radiation syndrome (ARS) is a major cause of lethality following radiation disasters. A TLR5 agonist, entolimod, is among the most powerful experimental radiation countermeasures and shows efficacy in rodents and non-human primates as a prophylactic (radioprotection) and treatment (radiomitigation) modality. While the prophylactic activity of entolimod has been connected to the suppression of radiation-induced apoptosis, the mechanism by which entolimod functions as a radiomitigator remains poorly understood. Uncovering this mechanism has significant and broad-reaching implications for the clinical development and improvement of TLR5 agonists for use as an effective radiation countermeasure in scenarios of mass casualty resulting from accidental exposure to ionizing radiation. Here, we demonstrate that in contrast to radioprotection, neutrophils are essential for the radiomitigative activity of entolimod in a mouse model of lethal ARS. Neutrophils express functional TLR5 and rapidly exit the bone marrow (BM), accumulate in solid tissues, and release MMP-9 following TLR5 stimulation which is accompanied by an increase in the number of active hematopoietic pluripotent precursors (HPPs) in the BM. Importantly, recombinant MMP-9 by itself has radiomitigative activity and, in the absence of neutrophils, accelerates the recovery of the hematopoietic system. Unveiling this novel TLR5-neutrophil-MMP-9 axis of radiomitigation opens new opportunities for the development of efficacious radiation countermeasures to treat ARS following accidental radiation disasters.<\/jats:p>","DOI":"10.1038\/s41420-021-00642-6","type":"journal-article","created":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T13:09:50Z","timestamp":1632834590000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Signaling through TLR5 mitigates lethal radiation damage by neutrophil-dependent release of MMP-9"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9897-5276","authenticated-orcid":false,"given":"Craig M.","family":"Brackett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kellee F.","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa R.","family":"Aldrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas H.","family":"Trageser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srabani","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Molodtsov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bojidar M.","family":"Kandar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyudmila G.","family":"Burdelya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8742-4708","authenticated-orcid":false,"given":"Scott I.","family":"Abrams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2548-0154","authenticated-orcid":false,"given":"Andrei V.","family":"Gudkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,28]]},"reference":[{"key":"642_CR1","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1080\/13543776.2017.1233178","volume":"26","author":"VK Singh","year":"2016","unstructured":"Singh VK, Garcia M, Wise SY, Seed TM. Medical countermeasures for unwanted CBRN exposures: Part I chemical and biological threats with review of recent countermeasure patents. Expert Opin Ther Pat. 2016;26:1431\u201347.","journal-title":"Expert Opin Ther Pat."},{"key":"642_CR2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1749-6632.2000.tb06175.x","volume":"899","author":"JF Weiss","year":"2000","unstructured":"Weiss JF, Landauer MR. Radioprotection by antioxidants. Ann N Y Acad Sci. 2000;899:44\u201360.","journal-title":"Ann N Y Acad Sci."},{"key":"642_CR3","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1093\/emboj\/16.6.1391","volume":"16","author":"EA Komarova","year":"1997","unstructured":"Komarova EA, Chernov MV, Franks R, Wang K, Armin G, Zelnick CR, et al. Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J. 1997;16:1391\u2013400.","journal-title":"EMBO J"},{"key":"642_CR4","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1080\/095530096144563","volume":"70","author":"JH Hendry","year":"1996","unstructured":"Hendry JH, Adeeko A, Potten CS, Morris ID. P53 deficiency produces fewer regenerating spermatogenic tubules after irradiation. Int J Radiat Biol. 1996;70:677\u201382.","journal-title":"Int J Radiat Biol"},{"key":"642_CR5","first-page":"179","volume":"6","author":"R Urbaschek","year":"1987","unstructured":"Urbaschek R, Mannel DN, Urbaschek B. Tumor necrosis factor induced stimulation of granulopoiesis and radioprotection. Lymphokine Res. 1987;6:179\u201386.","journal-title":"Lymphokine Res"},{"key":"642_CR6","doi-asserted-by":"publisher","first-page":"e30434","DOI":"10.1371\/journal.pone.0030434","volume":"7","author":"LA Basile","year":"2012","unstructured":"Basile LA, Ellefson D, Gluzman-Poltorak Z, Junes-Gill K, Mar V, Mendonca S, et al. HemaMax, a recombinant human interleukin-12, is a potent mitigator of acute radiation injury in mice and non-human primates. PloS ONE. 2012;7:e30434.","journal-title":"PloS ONE."},{"key":"642_CR7","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1128\/MCB.19.5.3485","volume":"19","author":"GA Webster","year":"1999","unstructured":"Webster GA, Perkins ND. Transcriptional cross talk between NF-kappaB and p53. Mol Cell Biol. 1999;19:3485\u201395.","journal-title":"Mol Cell Biol"},{"key":"642_CR8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1517\/17460441.2015.1023290","volume":"10","author":"VK Singh","year":"2015","unstructured":"Singh VK, Newman VL, Berg AN, MacVittie TJ. Animal models for acute radiation syndrome drug discovery. Expert Opin Drug Discov. 2015;10:497\u2013517.","journal-title":"Expert Opin Drug Discov"},{"key":"642_CR9","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.7326\/0003-4819-140-12-200406150-00015","volume":"140","author":"JK Waselenko","year":"2004","unstructured":"Waselenko JK, MacVittie TJ, Blakely WF, Pesik N, Wiley AL, Dickerson WE, et al. Medical management of the acute radiation syndrome: recommendations of the Strategic National Stockpile Radiation Working Group. Ann Intern Med. 2004;140:1037\u201351.","journal-title":"Ann Intern Med"},{"key":"642_CR10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1001\/dmp.2011.68","volume":"5","author":"N Dainiak","year":"2011","unstructured":"Dainiak N, Gent RN, Carr Z, Schneider R, Bader J, Buglova E, et al. First global consensus for evidence-based management of the hematopoietic syndrome resulting from exposure to ionizing radiation. Disaster Med Public Health Prep. 2011;5:202\u201312.","journal-title":"Disaster Med Public Health Prep"},{"key":"642_CR11","unstructured":"FDA approves radiation medical countermeasure [Internet]. Place unknown: U.S. Food & Drug Administration; 2015. FDA approves Neupogen for treatment of patients with radiation-induced myelosuppression following a radiological\/nuclear incident; 2019 April 30 [cited 2021 April 5]; Available from: https:\/\/www.fda.gov\/emergency-preparedness-and-response\/about-mcmi\/fda-approves-radiation-medical-countermeasure."},{"key":"642_CR12","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1126\/science.1154986","volume":"320","author":"LG Burdelya","year":"2008","unstructured":"Burdelya LG, Krivokrysenko VI, Tallant TC, Strom E, Gleiberman AS, Gupta D, et al. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science. 2008;320:226\u201330.","journal-title":"Science."},{"key":"642_CR13","doi-asserted-by":"publisher","first-page":"e0135388","DOI":"10.1371\/journal.pone.0135388","volume":"10","author":"VI Krivokrysenko","year":"2015","unstructured":"Krivokrysenko VI, Toshkov IA, Gleiberman AS, Krasnov P, Shyshynova I, Bespalov I, et al. The toll-like receptor 5 agonist entolimod mitigates lethal acute radiation syndrome in non-human primates. PLoS ONE. 2015;10:e0135388.","journal-title":"PLoS ONE"},{"key":"642_CR14","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1124\/jpet.112.196071","volume":"343","author":"VI Krivokrysenko","year":"2012","unstructured":"Krivokrysenko VI, Shakhov AN, Singh VK, Bone F, Kononov Y, Shyshynova I, et al. Identification of granulocyte colony-stimulating factor and interleukin-6 as candidate biomarkers of CBLB502 efficacy as a medical radiation countermeasure. J Pharm Exp Ther. 2012;343:497\u2013508.","journal-title":"J Pharm Exp Ther"},{"key":"642_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ijrobp.2011.05.055","volume":"83","author":"LG Burdelya","year":"2012","unstructured":"Burdelya LG, Gleiberman AS, Toshkov I, Aygun-Sunar S, Bapardekar M, Manderscheid-Kern P, et al. Toll-like receptor 5 agonist protects mice from dermatitis and oral mucositis caused by local radiation: implications for head-and-neck cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2012;83:228\u201334.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"642_CR16","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1667\/RR14514.1","volume":"187","author":"IA Toshkov","year":"2017","unstructured":"Toshkov IA, Gleiberman AS, Mett VL, Hutson AD, Singh AK, Gudkov AV, et al. Mitigation of radiation-induced epithelial damage by the TLR5 agonist entolimod in a mouse model of fractionated head and neck irradiation. Radiat Res. 2017;187:570\u201380.","journal-title":"Radiat Res"},{"key":"642_CR17","doi-asserted-by":"publisher","first-page":"802","DOI":"10.18632\/oncotarget.1773","volume":"5","author":"BM Kojouharov","year":"2014","unstructured":"Kojouharov BM, Brackett CM, Veith JM, Johnson CP, Gitlin II, Toshkov IA, et al. Toll-like receptor-5 agonist entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in mice. Oncotarget. 2014;5:802\u201314.","journal-title":"Oncotarget."},{"key":"642_CR18","doi-asserted-by":"publisher","first-page":"3831","DOI":"10.4049\/jimmunol.1003238","volume":"187","author":"N Fukuzawa","year":"2011","unstructured":"Fukuzawa N, Petro M, Baldwin WM 3rd, Gudkov AV, Fairchild RL. A TLR5 agonist inhibits acute renal ischemic failure. J Immunol. 2011;187:3831\u20139.","journal-title":"J Immunol"},{"key":"642_CR19","doi-asserted-by":"publisher","first-page":"E1857","DOI":"10.1073\/pnas.1222805110","volume":"110","author":"LG Burdelya","year":"2013","unstructured":"Burdelya LG, Brackett CM, Kojouharov B, Gitlin II, Leonova KI, Gleiberman AS, et al. Central role of liver in anticancer and radioprotective activities of toll-like receptor 5 agonist. Proc Natl Acad Sci USA. 2013;110:E1857\u201366.","journal-title":"Proc Natl Acad Sci USA"},{"key":"642_CR20","doi-asserted-by":"publisher","first-page":"e0227940","DOI":"10.1371\/journal.pone.0227940","volume":"15","author":"GJ Haderski","year":"2020","unstructured":"Haderski GJ, Kandar BM, Brackett CM, Toshkov IM, Johnson CP, Paszkiewicz GM, et al. TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects. PLoS ONE. 2020;15:e0227940.","journal-title":"PLoS ONE"},{"key":"642_CR21","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1182\/blood-2003-04-1115","volume":"103","author":"LM Pelus","year":"2004","unstructured":"Pelus LM, Bian H, King AG, Fukuda S. Neutrophil-derived MMP-9 mediates synergistic mobilization of hematopoietic stem and progenitor cells by the combination of G-CSF and the chemokines GRObeta\/CXCL2 and GRObetaT\/CXCL2delta4. Blood. 2004;103:110\u20139.","journal-title":"Blood."},{"key":"642_CR22","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1189\/jlb.0407247","volume":"83","author":"JM Daley","year":"2008","unstructured":"Daley JM, Thomay AA, Connolly MD, Reichner JS, Albina JE. Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J Leukoc Biol. 2008;83:64\u201370.","journal-title":"J Leukoc Biol"},{"key":"642_CR23","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.immuni.2018.02.002","volume":"48","author":"M Evrard","year":"2018","unstructured":"Evrard M, Kwok I, Chong SZ, Teng K, Becht E, Chen J, et al. Developmental analysis of bone marrow neutrophils reveals populations specialized in expansion, trafficking, and effector functions. Immunity. 2018;48:364\u201379.","journal-title":"Immunity."},{"key":"642_CR24","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1093\/intimm\/dxs068","volume":"24","author":"T Shibata","year":"2012","unstructured":"Shibata T, Takemura N, Motoi Y, Goto Y, Karuppuchamy T, Izawa K, et al. PRAT4A-dependent expression of cell surface TLR5 on neutrophils, classical monocytes and dendritic cells. Int Immunol. 2012;24:613\u201323.","journal-title":"Int Immunol"},{"key":"642_CR25","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S1097-2765(00)80136-7","volume":"2","author":"R Medzhitov","year":"1998","unstructured":"Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S, et al. MyD88 is an adaptor protein in the hToll\/IL-1 receptor family signaling pathways. Mol Cell. 1998;2:253\u20138.","journal-title":"Mol Cell"},{"key":"642_CR26","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.4049\/jimmunol.147.4.1369","volume":"147","author":"TW Kuijpers","year":"1991","unstructured":"Kuijpers TW, Hakkert BC, Hoogerwerf M, Leeuwenberg JF, Roos D. Role of endothelial leukocyte adhesion molecule-1 and platelet-activating factor in neutrophil adherence to IL-1-prestimulated endothelial cells. Endothelial leukocyte adhesion molecule-1-mediated CD18 activation. J Immunol. 1991;147:1369\u201376.","journal-title":"J Immunol"},{"key":"642_CR27","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1172\/JCI16510","volume":"111","author":"G Andonegui","year":"2003","unstructured":"Andonegui G, Bonder CS, Green F, Mullaly SC, Zbytnuik L, Raharjo E, et al. Endothelium-derived toll-like receptor-4 is the key molecule in LPS-induced neutrophil sequestration into lungs. J Clin Investig. 2003;111:1011\u201320.","journal-title":"J Clin Investig"},{"key":"642_CR28","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.4049\/jimmunol.155.3.1502","volume":"155","author":"SI Simon","year":"1995","unstructured":"Simon SI, Burns AR, Taylor AD, Gopalan PK, Lynam EB, Sklar LA, et al. L-selectin (CD62L) cross-linking signals neutrophil adhesive functions via the Mac-1 (CD11b\/CD18) beta 2-integrin. J Immunol. 1995;155:1502\u201314.","journal-title":"J Immunol"},{"key":"642_CR29","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/380720a0","volume":"380","author":"B Walcheck","year":"1996","unstructured":"Walcheck B, Kahn J, Fisher JM, Wang BB, Fisk RS, Payan DG, et al. Neutrophil rolling altered by inhibition of L-selectin shedding in vitro. Nature. 1996;380:720\u20133.","journal-title":"Nature."},{"key":"642_CR30","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1189\/jlb.1A0216-072R","volume":"100","author":"A Hernandez","year":"2016","unstructured":"Hernandez A, Bohannon JK, Luan L, Fensterheim BA, Guo Y, Patil NK, et al. The role of MyD88- and TRIF-dependent signaling in monophosphoryl lipid A-induced expansion and recruitment of innate immunocytes. J Leukoc Biol. 2016;100:1311\u201322.","journal-title":"J Leukoc Biol"},{"key":"642_CR31","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1182\/blood.V89.10.3503","volume":"89","author":"N Borregaard","year":"1997","unstructured":"Borregaard N, Cowland JB. Granules of the human neutrophilic polymorphonuclear leukocyte. Blood. 1997;89:3503\u201321.","journal-title":"Blood."},{"key":"642_CR32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/00062752-200101000-00005","volume":"8","author":"N Borregaard","year":"2001","unstructured":"Borregaard N, Theilgaard-Monch K, Sorensen OE, Cowland JB. Regulation of human neutrophil granule protein expression. Curr Opin Hematol. 2001;8:23\u20137.","journal-title":"Curr Opin Hematol"},{"key":"642_CR33","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1189\/jlb.69.6.851","volume":"69","author":"G Opdenakker","year":"2001","unstructured":"Opdenakker G, Van den Steen PE, Dubois B, Nelissen I, Van Coillie E, Masure S, et al. Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol. 2001;69:851\u20139.","journal-title":"J Leukoc Biol"},{"key":"642_CR34","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1165\/ajrcmb.20.3.3311","volume":"20","author":"J Pugin","year":"1999","unstructured":"Pugin J, Widmer MC, Kossodo S, Liang CM, Preas, Suffredini AF. Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators. Am J Respir Cell Mol Biol. 1999;20:458\u201364.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"642_CR35","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1189\/jlb.0605353","volume":"79","author":"S Chakrabarti","year":"2006","unstructured":"Chakrabarti S, Zee JM, Patel KD. Regulation of matrix metalloproteinase-9 (MMP-9) in TNF-stimulated neutrophils: novel pathways for tertiary granule release. J Leukoc Biol. 2006;79:214\u201322.","journal-title":"J Leukoc Biol"},{"key":"642_CR36","doi-asserted-by":"publisher","first-page":"10863","DOI":"10.1073\/pnas.96.19.10863","volume":"96","author":"JF Pruijt","year":"1999","unstructured":"Pruijt JF, Fibbe WE, Laterveer L, Pieters RA, Lindley IJ, Paemen L, et al. Prevention of interleukin-8-induced mobilization of hematopoietic progenitor cells in rhesus monkeys by inhibitory antibodies against the metalloproteinase gelatinase B (MMP-9). Proc Natl Acad Sci USA. 1999;96:10863\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"642_CR37","first-page":"765","volume":"25","author":"B Heissig","year":"2010","unstructured":"Heissig B, Nishida C, Tashiro Y, Sato Y, Ishihara M, Ohki M, et al. Role of neutrophil-derived matrix metalloproteinase-9 in tissue regeneration. Histol Histopathol. 2010;25:765\u201370.","journal-title":"Histol Histopathol"},{"key":"642_CR38","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0167-8140(87)80199-8","volume":"9","author":"J Dutreix","year":"1987","unstructured":"Dutreix J, Girinski T, Cosset JM, Bernard A, Pico J, Baume D, et al. Blood cell kinetics and total body irradiation. Radiother Oncol. 1987;9:119\u201329.","journal-title":"Radiother Oncol"},{"key":"642_CR39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1742-4658.2010.07919.x","volume":"278","author":"C Gialeli","year":"2011","unstructured":"Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011;278:16\u201327.","journal-title":"FEBS J"},{"key":"642_CR40","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S0092-8674(02)00754-7","volume":"109","author":"B Heissig","year":"2002","unstructured":"Heissig B, Hattori K, Dias S, Friedrich M, Ferris B, Hackett NR, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell. 2002;109:625\u201337.","journal-title":"Cell."},{"key":"642_CR41","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1101\/gad.815400","volume":"14","author":"TH Vu","year":"2000","unstructured":"Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev. 2000;14:2123\u201333.","journal-title":"Genes Dev"},{"key":"642_CR42","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.cell.2017.11.003","volume":"172","author":"J Hoggatt","year":"2018","unstructured":"Hoggatt J, Singh P, Tate TA, Chou BK, Datari SR, Fukuda S, et al. Rapid mobilization reveals a highly engraftable hematopoietic stem cell. Cell. 2018;172:191\u2013204.","journal-title":"Cell."},{"key":"642_CR43","doi-asserted-by":"crossref","unstructured":"Cottler-Fox MH, Lapidot T, Petit I, Kollet O, DiPersio JF, Link D, et al. Stem cell mobilization. Hematology Am Soc Hematol Educ Program. 2003:419\u201337.","DOI":"10.1182\/asheducation-2003.1.419"},{"key":"642_CR44","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.matbio.2015.01.011","volume":"44-46","author":"G Klein","year":"2015","unstructured":"Klein G, Schmal O, Aicher WK. Matrix metalloproteinases in stem cell mobilization. Matrix Biol. 2015;44-46:175\u201383.","journal-title":"Matrix Biol"},{"key":"642_CR45","doi-asserted-by":"publisher","first-page":"3249.","DOI":"10.3390\/s18103249","volume":"18","author":"H Huang","year":"2018","unstructured":"Huang H. Matrix metalloproteinase-9 (MMP-9) as a cancer biomarker and MMP-9 biosensors: recent advances. Sensors. 2018;18:3249.","journal-title":"Sensors"},{"key":"642_CR46","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2165\/00003495-200262001-00006","volume":"62","author":"P Anderlini","year":"2002","unstructured":"Anderlini P, Champlin R. Use of filgrastim for stem cell mobilisation and transplantation in high-dose cancer chemotherapy. Drugs. 2002;62:79\u201388.","journal-title":"Drugs"},{"key":"642_CR47","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1517\/14712598.2015.986453","volume":"15","author":"VK Singh","year":"2015","unstructured":"Singh VK, Romaine PL, Newman VL. Biologics as countermeasures for acute radiation syndrome: where are we now? Expert Opin Biol Ther. 2015;15:465\u201371.","journal-title":"Expert Opin Biol Ther"},{"key":"642_CR48","first-page":"160","volume":"167","author":"N Williams","year":"1992","unstructured":"Williams N, Bertoncello I, Jackson H, Arnold J, Kavnoudias H. The role of interleukin 6 in megakaryocyte formation, megakaryocyte development and platelet production. Ciba Found Symp. 1992;167:160\u201370.","journal-title":"Ciba Found Symp"},{"key":"642_CR49","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1200\/JCO.1993.11.3.499","volume":"11","author":"J Weber","year":"1993","unstructured":"Weber J, Yang JC, Topalian SL, Parkinson DR, Schwartzentruber DS, Ettinghausen SE, et al. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Oncol. 1993;11:499\u2013506.","journal-title":"J Clin Oncol"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-021-00642-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-021-00642-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-021-00642-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T16:48:16Z","timestamp":1673369296000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-021-00642-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,28]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["642"],"URL":"https:\/\/doi.org\/10.1038\/s41420-021-00642-6","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,28]]},"assertion":[{"value":"26 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AVG is a shareholder of Cleveland BioLabs, Inc. and Genome Protection, Inc., biotech companies that conduct clinical development of entolimod. Parts of this work performed in CMB and AVG labs were funded by contracts from Cleveland BioLabs, Inc. and Genome Protection, Inc. to Roswell Park Comprehensive Cancer Center. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"266"}}